๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› DLBCL
Clinical trial register · China

DLBCL Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 6 Guangzhou 4 Beijing 3 Nanjing 2 Chongqing 2
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai6 Guangzhou4 Beijing3 Nanjing2 Chongqing2
All 16 locations
Target enrolment
to

DLBCL trials in China

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT07570017DLBCL
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
42
Guangzhou, Shanghai
2026-06-25
Not yet open
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL
NCT07643805DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2
46
Nanjing
2026-06-01
Recruiting
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
NCT07162012NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), DLBCL
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
24
Shanghai
2025-09-20
Recruiting
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
NCT07070648Diffuse Large B-Cell Lymphoma, DLBCL
Fudan University
Observational
300
Shanghai
2025-05-09
Recruiting
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
NCT06758037DLBCL, Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Ningbo University
Phase 2
50
Ningbo
2025-01-15
Recruiting
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
NCT06779435DLBCL
Ruijin Hospital
Observational
400
Shanghai
2025-01-01
Not yet open
CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)
NCT06750991DLBCL
Ruijin Hospital
Phase 2
34
Shanghai
2024-12-31
Recruiting
CR-CHOP+X in Previously Untreated DEL
NCT06701357DLBCL
Ruijin Hospital
Phase 2
49
Shanghai
2024-12-10
Recruiting
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
NCT06569485DLBCL
Sun Yat-sen University
Phase 2
38
Guangzhou
2024-05-23
Recruiting
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255DLBCL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
244
Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-05-07
Recruiting
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
NCT05487170Advanced Solid Tumor, DLBCL
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
32
Beijing
2022-07-12
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Recruiting
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT05552937DLBCL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
50
Hangzhou
2021-09-06
Recruiting
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
NCT04432714DLBCL, Untreated, MYC Gene Rearrangement
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2
81
Nanjing
2020-06-09
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/dlbcl

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies listing the condition DLBCL.

How many DLBCL trials are recruiting in China?

13 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (DLBCL), 15 studies
PhaseStudiesRecruitingShare
Phase 25433.3%
Phase 1/24326.7%
Observational2213.3%
Phase 1116.7%
Phase 2/3116.7%
Phase 3116.7%
Phase EARLY_PHASE1116.7%

Most active sponsors

Lead sponsors with the most studies (DLBCL)
Lead sponsorStudiesRecruiting
Ruijin Hospital32
Beijing InnoCare Pharma Tech Co., Ltd.22
The First Affiliated Hospital with Nanjing Medical University21
First Affiliated Hospital of Ningbo University11
Fudan University11
Guangzhou Lupeng Pharmaceutical Company LTD.11
Institute of Hematology & Blood Diseases Hospital, China11
Merck Sharp & Dohme LLC11
Ranok Therapeutics (Hangzhou) Co., Ltd.11
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.